Leerink analyst Andrew Berens raised the firm’s price target on Zymeworks (ZYME) to $37 from $24 and keeps an Outperform rating on the shares after the company reported that Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival versus the control arm in the HERIZON-GEA-01 study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks’ Promising Clinical Trial Results and Market Potential Justify Buy Rating
- Zymeworks price target raised to $35 from $22 at Citi
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
- Zymeworks Announces Positive Phase 3 Trial Results